|Mr. Mark M. Sieczkarek||Chairman, CEO & Pres||453.5k||N/A||62|
|Mr. Justin M. Hall||Sr. VP & Gen. Counsel||253.5k||N/A||39|
|Mr. John J. McGovern||CFO, Treasurer & Principal Accounting Officer||N/A||N/A||N/A|
|Dr. David W. Stroman Ph.D.||Sr. VP of Ophthalmic Product Devel. and Chair of Ophthalmology Advisory Board||N/A||N/A||72|
|Mr. Lewis J. Stuart BA, MBA||Chief Commercial Officer||N/A||N/A||58|
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
NovaBay Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.